1.. Introduction {#S5}
================

A newly identified viral illness emerged in late December 2019 that has subsequently spread rapidly throughout the world \[[@R1]\]. A new coronavirus, later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the pathogen that caused severe respiratory illness also known as coronavirus disease 2019 or COVID-19 \[[@R2]\].

SARS-CoV-2 binds with high affinity to human angiotensin-converting enzyme 2 receptor (ACE 2) \[[@R3]\]. ACE-2 is widely expressed throughout the body, including in the lungs and the heart \[[@R4]\]. Although scarce, serious systemic infections such as myocarditis have been reported in connection with COVID-19.

Myocarditis, an inflammatory condition affecting the myocardium, results from a wide spectrum of both infectious and non-infectious causes. Many different viruses have been implicated, including the Middle East Respiratory Syndrome (MERS) coronavirus \[[@R5]\], which closely resembles SARS-CoV-2. Myocarditis is suspected on the basis of elevated troponins in the patient's blood, cardiac arrythmias or diffuse ST elevation on electrocardiogram (ECG) and left ventricular wall motion abnormalities (regional or global hypokinesis) on echocardiogram. The clinical presentations of myocarditis include subclinical, subacute, acute and fulminant forms, and abrupt-onset myocarditis is known to be associated with significant severity \[[@R6]\].

The annual incidence of acute myocarditis from all causes is approximately 22 cases per 100,000 population, with heart failure occurring in 0.5% to 4.0% of these cases \[[@R7]\]. Myocarditis can occur in 1% to 5% of all patients with acute viral infections \[[@R8]\]. To date, clinical data on myocarditis caused by SARS-CoV-2 is scarce. Patient characteristics, clinical course, degree of severity, imaging and electrocardiographic features, management and outcomes of myocarditis are just some of relevant data clinicians should have access to when treating patients with COVID-19 myocarditis. Therefore, we conducted a systematic review of myocarditis in COVID-19 patients to evaluate clinical features, diagnostic tests and current therapeutic management.

2.. Methods {#S6}
===========

2.1.. Protocol and Registration {#S7}
-------------------------------

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist was adhered to for this systematic review \[[@R9]\]. The protocol was not registered.

2.2.. Eligibility Criteria {#S8}
--------------------------

### 2.2.1.. Inclusion Criteria {#S9}

Only articles that reported myocardial inflammation or myocarditis in association with COVID-19 were included.

### 2.2.2.. Exclusion Criteria {#S10}

Studies were excluded if: 1) Articles were not case reports, case series or observational studies, or 2) Articles were reviews or editorials. The language the article was written in was not a limitation.

2.3.. Information Sources and Search Strategies {#S11}
-----------------------------------------------

A comprehensive literature search was completed using Medline/Pubmed, Google Scholar, CINAHL, Cochrane CENTRAL and Web of Science databases up to and including 29 April 2020, using the terms "Coronavirus" or "COVID" and "myocarditis," "heart" or "retrospective."

2.4.. Study Selection {#S12}
---------------------

Articles were triaged based on whether titles or abstracts met the inclusion criteria. Full-text articles were then read, and those that did not satisfy the inclusion criteria or fit exclusion criteria were excluded. A summary of study characteristics is included in [Table 1](#T1){ref-type="table"}.

2.5.. Data Collection Process and Data Items {#S13}
--------------------------------------------

Data extracted from articles included the name of first author, year and country of publication and study design. Patient variables including age, sex and presenting complaints on admission were sought from all studies. Laboratory tests and diagnostic studies, as well as myocarditis management strategies and patient outcomes, including complications, were obtained from case studies.

2.6.. Synthesis of Results and Summary of Measures {#S14}
--------------------------------------------------

Information was assessed if it was reported by two or more articles. Data were tabulated, evaluated and summarized. From the retrospective studies, for Deng et al. \[[@R10]\] the diagnosis of myocarditis was assumed, while Ruan et al. \[[@R11]\] gathered patient profiles and presenting symptoms from the deceased population.

2.7.. Risk of Bias of the Included Studies {#S15}
------------------------------------------

Potential biases of the included studies were analyzed utilizing the study characteristics. Two independent reviewers evaluated the methodological quality of the eligible studies. A third reviewer evaluated papers for which no decision regarding bias could be reached. The Joanna Briggs Institute critical appraisal tool for case reports was selected for use in this systematic review \[[@R12]\]. The presence of a bias was determined for each article using a checklist the eight questions included in [Table 1](#T1){ref-type="table"}. The articles received scores to indicate their degree of biases; low (included), high (excluded) or uncertain (more information is required). For the purpose of this study, if "yes" was answered for half or more of the eight questions on the checklist, the study was considered to be at low risk of bias. Similarly, an answer of "no" to half or more of the eight questions meant the study was determined to be at high risk of bias. Whereas "unclear" answers were equal to or greater than 50% response.

3.. Results {#S16}
===========

3.1.. Study Selection {#S17}
---------------------

Five databases were used to find the 1076 articles related to COVID-19 and myocarditis. Eleven studies were then deemed eligible for inclusion in this review \[[@R10],[@R11],[@R13],[@R14],[@R15],[@R16],[@R17],[@R18],[@R19],[@R20],[@R21]\]. A PRISMA flow diagram detailing the process of identification, inclusion and exclusion of studies is shown in [Figure 1](#F1){ref-type="fig"}.

3.2.. Study Characteristics {#S18}
---------------------------

Of the 11 included articles, nine were case reports \[[@R13],[@R14],[@R15],[@R16],[@R17],[@R18],[@R19],[@R20],[@R21]\] and two were retrospective studies \[[@R10],[@R11]\]. All but one \[[@R21]\] were peer-reviewed. All articles were published in 2020. Five studies were conducted in Asia \[[@R10],[@R11],[@R14],[@R17],[@R21]\] and six were conducted in Europe \[[@R13],[@R15],[@R16],[@R18],[@R19],[@R20]\]. China produced the most articles \[[@R10],[@R11],[@R14],[@R21]\] followed by Italy \[[@R15],[@R19],[@R20]\].

3.3.. Risk of Bias within the Studies {#S19}
-------------------------------------

In comparison of the case reports, the majority of articles were determined to have low risk of bias \[[@R13],[@R14],[@R15],[@R16],[@R18],[@R19],[@R20],[@R21]\]. Only one study was identified as having high risk of bias \[[@R17]\]. Both retrospective studies were rated as having high risk of bias \[[@R10],[@R11]\]. These results are included in [Table 1](#T1){ref-type="table"}.

3.4.. Results of Individual Studies {#S20}
-----------------------------------

Nine case reports were selected for the systematic review. In the French study by Doyen et al. \[[@R13]\], the authors described a 69-year-old Italian man who tested positive for COVID-19, developed elevated troponins and ECG changes and was managed with hydrocortisone. Hu et al. \[[@R14]\] reported a case of a 37-year-old COVID-19 male from China with fulminant myocarditis who was treated with glucocorticoids and intravenous human immunoglobulin. Inciardi et al. \[[@R15]\] reported a 53-year-old Italian woman with COVID-19 with acute myopericarditis with evidence of systolic dysfunction on echocardiogram. In the only article not written in English, Irabien-Ortiz et al. \[[@R16]\] described a 59-year-old woman from Spain with COVID-19 and fulminant myocarditis in the absence of initial respiratory symptoms. In the study by Kim et al. \[[@R17]\], a 21-year-old woman from South Korea presented with COVID-19 and myocarditis. In the French study by Paul et al. \[[@R18]\], the authors reported a 35-year-old male positive for COVID-19 with acute myocarditis without fever, cough or pulmonary involvement. The article by Sala et al. \[[@R19]\] described a 43-year-old Italian woman diagnosed with COVID-19 and acute virus-negative lymphocytic myocarditis. Tavazzi et al. \[[@R20]\] described a case of a 69-year-old Italian woman with COVID-19 and low-grade myocardial inflammation; viral particles were seen in the patient's myocardium and the she required venous-arterial extracorporeal membrane oxygenation. Finally, Zeng et al. \[[@R21]\] reported a 63-year-old Chinese man with COVID-19 complicated by fulminant myocarditis.

Two retrospective studies were selected for the systematic review. In the first study, Deng et al. \[[@R10]\] described 14 of the original 112 patients hospitalized with COVID-19 in a major tertiary teaching hospital in China, who presented with cardiac abnormalities similar to myocarditis. In the second retrospective study Ruan et al. \[[@R11]\] reported that some of the 150 COVID-19 positive patients from two hospitals in China died of fulminant myocarditis. A summary of findings from all studies is presented in [Table 2](#T2){ref-type="table"}.

3.5.. Synthesis of Results {#S21}
--------------------------

### 3.5.1.. Patient Profiles {#S22}

Among the nine case reports, COVID-19 patients with myocarditis were 51.8 ± 16.9 years of age, and males and females were equally affected \[[@R13],[@R14],[@R15],[@R16],[@R17],[@R19],[@R20],[@R21]\]. In contrast, the retrospective studies described the typical myocarditis patient as male and older than 55 years of age \[[@R10],[@R11]\]. The youngest patient described with COVID-19-related myocarditis was a 21-year old woman \[[@R17]\].

### 3.5.2.. Presenting Complaints {#S23}

The predominant complaint on presentation was dyspnea \[[@R10],[@R11],[@R13],[@R14],[@R16],[@R17],[@R19],[@R20],[@R21]\], followed by coughing \[[@R10],[@R11],[@R15],[@R17],[@R20],[@R21]\], fever \[[@R10],[@R11],[@R13],[@R14],[@R15],[@R17],[@R21]\], and chest pain \[[@R10],[@R13],[@R16],[@R19],[@R21]\]. The mean temperature recorded was 37.53 ± 1.3°C \[[@R10],[@R15],[@R19],[@R20],[@R21]\], and the mean blood pressure was 85/58.3 ± 22.4/14.6 \[[@R10],[@R14],[@R15],[@R16],[@R19],[@R20]\]. The distribution of presenting complaints and associated symptoms is found in [Table 3](#T3){ref-type="table"}.

### 3.5.3.. Past Medical History {#S24}

There were insufficient data regarding past medical history.

### 3.5.4.. Laboratory Tests {#S25}

A summary of laboratory tests is found in [Table 4](#T4){ref-type="table"}. Mean white blood cell (WBC) count was elevated at 17,383 ± 4,947 cells/mm^3^ \[[@R16],[@R20]\], and C-reactive protein (CRP) levels were increased at 31.2 ± 20.0 mg/L \[[@R13],[@R15],[@R19],[@R20]\]. Arterial blood gas analyses showed respiratory acidosis with a mean pH of 7.24 ± 0.17 \[[@R13],[@R15],[@R20],[@R21]\] and mean pCO~2~ of 51.2 ± 8.2 mmHg \[[@R13],[@R15],[@R21]\]. Average oxygen saturation was 94.6 ± 4.1% \[[@R13],[@R15],[@R16],[@R19],[@R21]\], with a pO~2~ of 91.0 ± 37.2 mmHg \[[@R13],[@R15],[@R20],[@R21]\]. All studies reported either increased troponin-I \[[@R13],[@R17],[@R20],[@R21]\] or troponin-T \[[@R14],[@R15],[@R16],[@R19]\], along with elevated creatinine kinase-myocardial band (CK-MB) \[[@R14],[@R15],[@R21]\] and brain natriuretic peptide (BNP) \[[@R14],[@R15],[@R16],[@R17],[@R19],[@R20],[@R21]\].

### 3.5.5.. Diagnostic Studies {#S26}

A list of the diagnostic tests and imaging techniques utilized in the studies is provided in [Table 5](#T5){ref-type="table"}. All patients were confirmed COVID-19 positive. Bilateral infiltrates were discovered in 50% of chest radiographs \[[@R17],[@R19],[@R21]\] and bilateral ground glass opacities were seen in all patients who underwent chest computed tomography (CT) \[[@R13],[@R14],[@R17],[@R19],[@R20],[@R21]\].

Cardiac magnetic resonance imaging (MRI) revealed late gadolinium enhancement \[[@R13],[@R15],[@R17],[@R18],[@R19]\] in all of the patients, while myocardial edema was identified in more than half of the images \[[@R15],[@R17],[@R19]\]. Fifty percent of the imaging studies revealed cardiomegaly or vascular redistribution \[[@R14],[@R16],[@R17]\]. Coronary artery stenosis was not appreciated on the CT angiography studies \[[@R14],[@R17],[@R19]\].

Electrocardiograms revealed ST-segment elevation in five cases \[[@R14],[@R15],[@R16],[@R18],[@R19]\], and inverted T waves in three cases \[[@R13],[@R15],[@R20]\]. In six of the studies, 2-D echocardiography revealed decreased left ventricular ejection fraction (LVEF) \[[@R14],[@R15],[@R17],[@R19],[@R20],[@R21]\], and in the same number of cases, cardiomegaly or increased wall thickness were observed \[[@R13],[@R14],[@R15],[@R16],[@R20],[@R21]\]. Pericardial effusion was present in only three patients \[[@R14],[@R15],[@R16]\]. Two studies reported the results of endomyocardial biopsies \[[@R19],[@R20]\]; both samples revealed active inflammation, and only one found viral particles within the myocardium \[[@R20]\].

### 3.5.6.. Management of Myocarditis {#S27}

Corticosteroids were utilized in attempted treatment in 75% of studies \[[@R13],[@R14],[@R15],[@R16],[@R20],[@R21]\], while the use of the antiviral medications lopinavir-ritonavir was reported in 62.5% of studies \[[@R14],[@R15],[@R16],[@R19],[@R20],[@R21]\]. The utilization of hydroxychloroquine \[[@R15],[@R19],[@R20]\], human immunoglobulin \[[@R14],[@R16],[@R21]\], piperacillin-tazobactam \[[@R14],[@R20],[@R21]\], and extracorporeal membrane oxygenation \[[@R16],[@R20],[@R21]\] each as single therapeutic interventions was described in 37.5% of case reports. The use of inotropes and/or vasopressors was reported in 50% of studies \[[@R14],[@R15],[@R16],[@R20]\].

### 3.5.7.. Outcome {#S28}

Patient outcomes were included in the majority of the case reports \[[@R13],[@R14],[@R17],[@R18],[@R19],[@R20],[@R21]\]. Only one death was reported, and it was non-myocarditis-related \[[@R20]\]. The remaining articles reported either recovery \[[@R14],[@R15],[@R16],[@R19],[@R21]\] or no further impairment of LVEF \[[@R20]\].

3.6.. Risk of Bias across the Studies {#S29}
-------------------------------------

Due to the nature of the descriptive studies, the results presented are liable to investigator bias, selection procedure bias and selection bias.

### 3.6.1.. Limitation of the Study {#S30}

Statistical analyses were not performed as there were no control/comparison groups in the included studies.

4.. Discussion {#S31}
==============

In order of prevalence, the clinical manifestations of the severe acute respiratory syndrome due to COVID-19 are fever, cough and fatigue \[[@R22]\]. Typically, myocarditis presents with fever, dyspnea and/or chest pain \[[@R23]\], which hampers the recognition and clinical diagnosis of myocarditis during the COVID-19 pandemic. We have identified through this systematic review that patients with COVID-19 myocarditis will commonly present with dyspnea, followed by coughing, fever and chest pain.

Serum biomarkers are conventionally used to confirm suspected acute myocarditis. While troponin was elevated in a few patients with acute myocarditis \[[@R24]\], elevated serum cardiac troponins were almost always seen in fulminant myocarditis \[[@R6]\]. Heightened levels of troponins have been described in many patients infected with COVID-19, with particular differences observed between deceased and surviving patients \[[@R25]\]. The absence of increased serum cardiac troponins, however, does not rule out myocarditis \[[@R6]\]. Elevated CK-MB and BNP were often elevated in myocarditis and can provide insight into prognosis \[[@R26]\]. CRP was commonly elevated, although normal levels did not exclude myocarditis \[[@R27]\]. CRP has been shown to be above the normal range in most COVID-19 patients as well \[[@R22]\]. This systematic review revealed increases in troponins, CK-MB, BNP, and CRP in COVID-19 myocarditis.

ST-segment abnormalities on ECG were demonstrated in 71.4% of patients. The ECGs of most patients with myocarditis demonstrated non-specific features including sinus tachycardia, ST-wave and T-wave abnormalities, and occasional atrioventricular or bundle branch block \[[@R28]\]. While ST-segment elevations in contiguous leads in a segmental fashion or in a nonvascular distribution are common electrocardiographic signs of myocarditis, they can often be mistaken for coronary occlusion \[[@R6]\].

Echocardiographic patterns of dilated, hypertrophic, restrictive and ischemic cardiomyopathies, particularly increased sphericity and left ventricular volume, have been described in histologically proven myocarditis \[[@R29]\]. Impaired LVEF on presentation is an independent predictor of a fulminant disease course \[[@R30]\]. This systematic review found that the majority of COVID-19 myocarditis patients had cardiomegaly, pleural effusion and reduced LVEF.

Dilated ventricles are typical of acute myocarditis, although the fulminant form can lead to increased left ventricular wall thickness as a result of active inflammation \[[@R29]\]. The majority of the cases of COVID-19 myocarditis reviewed here displayed cardiomegaly. Furthermore, the development of pneumonia seen as ground glass opacities on chest CT, the characteristic feature of COVID-19, was found in all patients in this systematic review \[[@R22],[@R31]\].

There are only a few prospective blinded randomized trials that have specifically targeted viral infections or the associated inflammatory cascades in myocarditis. Presently, evidence does not support the routine use of corticosteroids or intravenous immunoglobulin alone \[[@R32],[@R33]\], although combined treatment of corticosteroids with immunosuppressants has shown non-significant increases in LVEF \[[@R32]\]. The use of extracorporeal membrane oxygenation, however, has been shown to provide favorable outcomes for patients with myocarditis and sepsis \[[@R34]\], as well as fulminant myocarditis \[[@R35]\].

Among COVID-19 patients, there is limited evidence of the effectiveness of current management and treatment strategies. A recently published systematic review concluded that treatment with corticosteroids, mainly methylprednisolone, in patients infected with a coronavirus like COVID-19, SARS, MERS, etc., is associated with higher mortality, longer hospitalization, and higher rates of bacterial infection and electrolyte abnormalities \[[@R36]\]. A combination treatment of steroids with immunomodulatory therapy and antibiotics was used in a minority of studies. Extracorporeal membrane oxygenation was used in three studies with mixed results.

It is difficult to evaluate the effectiveness of the various treatment strategies currently being attempted in cases of COVID-19 given the lack of randomized control trial results to date. While current evidence shows no significant difference in the prognosis of virus-positive and virus-negative patients with myocarditis \[[@R37]\], that may change within the COVID-19 climate.

In conclusion, our systematic review provides a comprehensive characterization of clinical features among COVID-19 patients with myocarditis. Data are presently limited, therefore more research, particularly of the epidemiological type, is needed to improve our understanding of COVID-19 myocarditis.
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###### 

Summary Assessment of the Risk of Bias for the Included Studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference, publication year        Were the patient's\        Was the patient's history\   Was the patient's clinical\   Were diagnostic tests or\           Was the intervention or\   Was the post-\           Were adverse events\        Does the case report\   Total score
                                     demographic\               clearly described and\       condition on presentation\    assessment methods and\             treatment procedure(s)\    intervention clinical\   (harms) or unanticipated\   provide takeaway\       
                                     characteristics clearly\   presented as a timeline?     clearly described?            results clearly described?          clearly described?         condition clearly\       events identified and\      lessons?                
                                     described?                                                                                                                                           described?               described?                                          
  ---------------------------------- -------------------------- ---------------------------- ----------------------------- ----------------------------------- -------------------------- ------------------------ --------------------------- ----------------------- -------------
  Deng et al., 2020 \[[@R10]\]       ✓                          Medical hx unknown           ✓                             All laboratory tests not included   No                         No                       No                          ✓                       37.50%

  Doyen et al., 2020 \[[@R13]\]      ✓                          ✓                            ✓                             All laboratory tests not included   ✓                          ✓                        ✓                           ✓                       87.50%

  Hu et al., 2020 \[[@R14]\]         ✓                          Medical hx unknown           ✓                             All laboratory tests not included   ✓                          ✓                        ✓                           ✓                       75%

  Inciardi et al., 2020 \[[@R15]\]   ✓                          ✓                            ✓                             ✓                                   ✓                          Outcome\                 ✓                           ✓                       87.50%
                                                                                                                                                                                          unknown                                                                      

  Irabien-Ortiz et al., 2020\        ✓                          ✓                            ✓                             All laboratory tests not included   ✓                          Outcome\                 ✓                           No                      62.50%
  \[[@R16]\]                                                                                                                                                                              unknown                                                                      

  Kim et al., 2020 \[[@R17]\]        ✓                          Medical hx unknown           ✓                             All laboratory tests not included   No                         No                       No                          No                      25%

  Paul et al., 2020 \[[@R18]\]       ✓                          ✓                            ✓                             All laboratory tests not included   ✓                          ✓                        ✓                           No                      75%

  Ruan et al., 2020 \[[@R11]\]       No                         No                           No                            ✓                                   ✓                          No                       No                          ✓                       37.50%

  Sala et al., 2020 \[[@R19]\]       ✓                          ✓                            ✓                             All laboratory tests not included   ✓                          ✓                        ✓                           No                      75%

  Tavazzi et al., 2020 \[[@R20]\]    Sex\                       ✓                            ✓                             All laboratory tests not included   ✓                          ✓                        ✓                           ✓                       75%
                                     Missing                                                                                                                                                                                                                           

  Zeng et al., 2020 \[[@R21]\]       ✓                          ✓                            Admission\                    All laboratory tests not included   Dosage\                    ✓                        ✓                           ✓                       63%
                                                                                             vitals\                                                           missing                                                                                                 
                                                                                             missing                                                                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of Included Articles

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference number &\                     Country       Type of study                        Patient profile (age\   Diagnosis
  publication year                                                                           in years, sex)          
  --------------------------------------- ------------- ------------------------------------ ----------------------- -------------------------------------------------------
  Deng et al., 2020 \[[@R10]\]            China         Retrospective study, single center   74, male                Possible myocarditis

  Doyen et al., 2020 \[[@R13]\]           France        Case report                          69, male                Acute myocarditis

  Hu et al., 2020 \[[@R14]\]              China         Case report                          37, male                Fulminant myocarditis

  Inciardi et al., 2020 \[[@R15]\]        Italy         Case report                          53, female              Acute myopericarditis

  Irabien-Ortiz et al., 2020 \[[@R16]\]   Spain         Case report                          59, female              Fulminant myocarditis

  Kim et al., 2020 \[[@R17]\]             South Korea   Case report                          21, female              Acute myocarditis

  Paul et al., 2020 \[[@R18]\]            France        Case report                          35, male                Acute myocarditis

  Ruan et al., 2020 \[[@R11]\]            China         Retrospective study, multi-center    Unknown                 Possible fulminant myocarditis

  Sala et al., 2020 \[[@R19]\]            Italy         Case report                          43, female              Acute virus-negative lymphocytic myocarditis

  Tavazzi et al., 2020 \[[@R20]\]         Italy         Case report                          69, female              Myocardial localization of virus in cardiogenic shock

  Zeng et al., 2020 \[[@R21]\]            China         Case report, non-peer reviewed       63, male                Fulminant myocarditis
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Most common clinical manifestations among patients with COVID-19 and myocarditis on admission as reported from all articles

  Symptom      \%
  ------------ -------------------------------------------------------------------------
  Dyspnea      81.8 \[[@R10],[@R11],[@R13],[@R14],[@R16],[@R17],[@R19],[@R20],[@R21]\]
  Fever        54.6 \[[@R10],[@R11],[@R13],[@R15],[@R17],[@R21]\]
  Cough        54.6 \[[@R10],[@R11],[@R15],[@R17],[@R20],[@R21]\]
  Chest pain   54.6 \[[@R10],[@R14],[@R16],[@R18],[@R19],[@R21]\]

###### 

Trends of laboratory values of COVID-19 patients with myocarditis

  -----------------------------------------------------------------------------------------------------------------
                                   Trends                                                          (Standard\
                                                                                                   range)
  -------------------------------- --------------------------------------------------------------- ----------------
  **Vitals**                                                                                       

  Temperature, Celsius             Elevated \[[@R13],[@R15],[@R19],[@R20],[@R21]\]                 (\<37.5)

  Systolic blood pressure, mmHg    Decreased \[[@R14],[@R15],[@R16],[@R19],[@R20]\]                (90-120)

  Diastolic blood pressure, mmHg   Decreased \[[@R14],[@R15],[@R16],[@R19]\]                       (60-80)

  **Arterial blood gas**                                                                           

  pH                               Low \[[@R13],[@R15],[@R20],[@R21]\]                             (7.35-7.45)

  pCO2, mmHg                       High \[[@R13],[@R15],[@R21]\]                                   (35-45)

  pO2, mmHg                        Normal \[[@R13],[@R15],[@R20],[@R21]\]                          (75-100)

  SaO2, %                          Normal \[[@R13],[@R15],[@R16],[@R19]\]                          (\>94)

  **Inflammatory markers**                                                                         

  WBC, cells/mm3                   Elevated \[[@R13],[@R16],[@R20]\]                               (4,500-11,000)

  CRP, mg/L                        Elevated \[[@R15],[@R19],[@R20]\]                               (\<8.0)

  **Cardiac markers**                                                                              

  Troponin-I, ng/mL                Elevated \[[@R13],[@R17],[@R18],[@R20],[@R21]\]                 (\<0.04)

  Troponin-T, ng/mL                Elevated \[[@R14],[@R15],[@R16],[@R19]\]                        (\<0.01)

  CK-MB, ng/mL                     Elevated \[[@R14],[@R15],[@R21]\]                               (\<5.0)

  BNP, pg/mL                       Elevated \[[@R14],[@R15],[@R16],[@R17],[@R19],[@R20],[@R21]\]   \<125
  -----------------------------------------------------------------------------------------------------------------

###### 

Common findings on diagnostic tests of COVID-19 patients with myocarditis

  ---------------------------------------------------------------------------------------------------
  Tests                                          Proportion Recorded\
                                                 from Articles Reviewed
  ---------------------------------------------- ----------------------------------------------------
  Imaging (X-ray, CT, MRI)                       

  Late gadolinium enhancement                    100 \[[@R13],[@R15],[@R17],[@R18],[@R19]\]

  Bilateral infiltrates/ground glass opacities   66.7 \[[@R13],[@R14],[@R17],[@R19],[@R20],[@R21]\]

  Cardiomegaly                                   33.3 \[[@R14],[@R15],[@R17]\]

  Echocardiography                               

  Decreased LVEF                                 66.7 \[[@R14],[@R15],[@R17],[@R19],[@R20],[@R21]\]

  Cardiomegaly or wall thickness                 66.7 \[[@R13],[@R14],[@R15],[@R16],[@R20],[@R21]\]

  Pericardial effusion                           33.3 \[[@R14],[@R15],[@R16]\]

  Electrocardiography                            

  ST-segment elevation                           55.6 \[[@R14],[@R15],[@R16],[@R18],[@R19]\]

  T-wave inversion                               33.3 \[[@R13],[@R15],[@R20]\]
  ---------------------------------------------------------------------------------------------------
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